Maven Securities LTD Makes New $1.30 Million Investment in MBX Biosciences, Inc. (NYSE:MBX)

Maven Securities LTD bought a new position in shares of MBX Biosciences, Inc. (NYSE:MBX - Free Report) during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund bought 50,000 shares of the company's stock, valued at approximately $1,299,000. Maven Securities LTD owned 0.15% of MBX Biosciences at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in MBX. Point72 Asia Singapore Pte. Ltd. purchased a new position in MBX Biosciences in the third quarter worth $278,000. The Manufacturers Life Insurance Company purchased a new position in shares of MBX Biosciences in the 3rd quarter valued at about $1,200,000. Finally, NEA Management Company LLC acquired a new stake in shares of MBX Biosciences in the third quarter valued at about $93,904,000.

Analyst Ratings Changes

A number of brokerages have issued reports on MBX. JPMorgan Chase & Co. initiated coverage on shares of MBX Biosciences in a report on Tuesday, October 8th. They issued an "overweight" rating and a $30.00 target price for the company. Jefferies Financial Group initiated coverage on MBX Biosciences in a report on Tuesday, October 8th. They set a "buy" rating and a $35.00 price objective for the company. Guggenheim began coverage on MBX Biosciences in a research note on Tuesday, October 8th. They set a "buy" rating and a $44.00 price target for the company. Finally, Stifel Nicolaus began coverage on shares of MBX Biosciences in a research note on Tuesday, October 8th. They issued a "buy" rating and a $40.00 price objective on the stock.

Insider Activity

In related news, major shareholder Life Sciences X. L.P. Frazier purchased 625,000 shares of the business's stock in a transaction on Monday, September 16th. The shares were bought at an average price of $16.00 per share, with a total value of $10,000,000.00. Following the completion of the purchase, the insider now directly owns 4,552,774 shares in the company, valued at approximately $72,844,384. This trade represents a 15.91 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Edward T. Mathers purchased 500,000 shares of the firm's stock in a transaction on Monday, September 16th. The stock was bought at an average price of $16.00 per share, for a total transaction of $8,000,000.00. Following the acquisition, the director now owns 3,614,486 shares in the company, valued at $57,831,776. The trade was a 16.05 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

MBX Biosciences Stock Up 0.3 %

Shares of MBX traded up $0.05 during trading hours on Thursday, reaching $19.29. 102,330 shares of the company traded hands, compared to its average volume of 120,876. The company's fifty day moving average price is $21.73. MBX Biosciences, Inc. has a fifty-two week low of $15.31 and a fifty-two week high of $27.50.

MBX Biosciences (NYSE:MBX - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($2.78) earnings per share for the quarter, missing analysts' consensus estimates of ($2.72) by ($0.06). As a group, equities analysts expect that MBX Biosciences, Inc. will post -13.21 EPS for the current fiscal year.

MBX Biosciences Company Profile

MBX Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.